Entry Rationale
The current stock price has surpassed the resistance level of $84.44, confirming a very strong buying momentum, which prompted consideration for entry.
Halozyme projects 2026 non-GAAP EPS of $8.65-$9.00 while raising revenue outlook to $1.835B-$1.91B
Halozyme has raised its 2026 non-GAAP EPS forecast to a range of $8.65 to $9.00 and adjusted its revenue outlook to between $1.835 billion and $1.910 billion.
The current stock price has surpassed the resistance level of $84.44, confirming a very strong buying momentum, which prompted consideration for entry.
The current stock price is showing strong buying pressure, so I will monitor the resistance level around $84.44 or any additional upward momentum. If it reaches the profit-taking target of $84.44, I will take profits, and if the support level of $73.89 is breached, I will cut losses.
RSI(14) is 74.5, moving averages are in a positive alignment, trading volume is 0.74 times the 20-day average, and the recent 7-day volatility is +2.6%.
At the time of the forecast, we approached the stock based on a clear positive outlook stemming from the upward revision of the 2026 non-GAAP EPS forecast and revenue estimates, supported by strong buying pressure exceeding the resistance level of $84.44. However, the actual result recorded an OVERHIT of 18.6%, significantly surpassing the predicted return of 2.5%. At the time of entry, the RSI (14) was already at a high level of 74.5, and the trading volume was somewhat subdued at 0.74 times the 20-day average. Despite this, the stock price surged immediately after the earnings announcement (2026-08-07 opening price $90.0, high $103.3, closing price $103.12), and we were unable to fully anticipate the explosive market reaction.
In the upcoming trades, when accompanied by strong earnings guidance upgrades, we will be cautious not to underestimate the upward potential due to technical indicators showing overbought conditions (RSI 74.5) or low trading volume ratios. Additionally, we will actively incorporate a more flexible approach to target price adjustments in response to significant positive developments.